Tactile Systems Technology, Inc. Reports Preliminary Full Year and Fourth Quarter 2018 Revenue Results
Preliminary Full Year 2018 Revenue Summary:
- Full year 2018 total revenue is expected to be in the range of
$142.8million to $143.3 million, representing growth of approximately 31% year-over-year. 2018 revenue is expected to be comprised of:
-- Flexitouch system revenue in the range of
$131.3million to $131.8 million, representing growth of approximately 31% year-over-year
-- Entre and Actitouch systems revenue of
$11.5 million, representing growth of approximately 29% year-over-year
Preliminary Fourth Quarter Revenue Summary:
- Fourth quarter total revenue is expected to be in the range of
$45.5million to $46.0 million, representing growth of approximately 30% to 32% year-over-year. Fourth quarter revenue is expected to be comprised of:
-- Flexitouch system revenue in the range of
$42.1million to $42.6 million, representing growth of approximately 30% to 31% year-over-year
-- Entre and Actitouch systems revenue of approximately
$3.4 million, representing growth of approximately 38% year-over-year
“We are excited to close the year with another quarter of strong execution, with revenue growth in excess of 30%, driven by sales of our Flexitouch systems,” said
Mr. Mattys continued: “Looking ahead to 2019, we remain confident in our ability to deliver 20% plus revenue growth and improving profitability as we continue to expand our share of the $4+ billion U.S. market in lymphedema and chronic venous insufficiency.”
This financial information is preliminary and subject to completion of the company’s year-end financial reporting processes and audit. Tactile Medical intends to report its full year and fourth quarter 2018 financial results in February and will provide the anticipated report date in a subsequent press release.
Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “confident,” “outlook” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the
Source: Tactile Systems Technology, Inc.